Everi - EVRI Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Everi in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EVRI shares.
View EVRI analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 1 year price targets for Everi's stock. Their EVRI share price forecasts range from $24.00 to $35.00. On average, they predict the company's share price to reach $28.00 in the next year. This suggests a possible upside of 64.3% from the stock's current price.
View analysts price targets for EVRI or view top-rated stocks among Wall Street analysts.

Everi's stock was trading at $14.35 at the start of the year. Since then, EVRI stock has increased by 18.7% and is now trading at $17.04.
View the best growth stocks for 2023 here.

Everi saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 2,330,000 shares, a decrease of 7.2% from the December 31st total of 2,510,000 shares. Based on an average daily trading volume, of 664,300 shares, the short-interest ratio is presently 3.5 days. Approximately 2.7% of the shares of the stock are short sold.
View Everi's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our EVRI earnings forecast.

Everi Holdings Inc. (NYSE:EVRI) posted its quarterly earnings data on Tuesday, November, 8th. The credit services provider reported $0.30 EPS for the quarter, missing the consensus estimate of $0.35 by $0.05. The credit services provider had revenue of $204.32 million for the quarter, compared to analyst estimates of $196.66 million. Everi had a net margin of 23.80% and a trailing twelve-month return on equity of 57.84%.

75 employees have rated Everi Chief Executive Officer Michael D. Rumbolz on Glassdoor.com. Michael D. Rumbolz has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Everi investors own include Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Organigram (OGI), New Residential Investment (NRZ), General Electric (GE), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), Sorrento Therapeutics (SRNE) and Nokia Oyj (NOK).

Everi trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVRI."

Everi's stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.49%), Ziegler Capital Management LLC (0.49%), Strs Ohio (0.23%), Counterpoint Mutual Funds LLC (0.02%), LVW Advisors LLC (0.01%) and Lindbrook Capital LLC (0.00%). Insiders that own company stock include Darren Simmons, David Lucchese, Dean A Ehrlich, Eileen F Raney, Geoffrey P Judge, Harper H Ko, Linster W Fox, Mark F Labay, Maureen T Mullarkey, Michael D Rumbolz, Randy L Taylor, Ronald V Congemi and Todd A Valli.
View institutional ownership trends.

Shares of EVRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVRI stock can currently be purchased for approximately $17.04.

Everi (NYSE:EVRI) has a market capitalization of $1.52 billion and generates $660.39 million in revenue each year. The credit services provider earns $152.93 million in net income (profit) each year or $1.82 on an earnings per share basis.

The company employs 1,550 workers across the globe.

Everi's mailing address is 7250 S. Tenaya Way Suite 100, Las Vegas NV, 89113. The official website for the company is www.everi.com. The credit services provider can be reached via phone at (800) 833-7110, via email at evri@jcir.com, or via fax at 866-672-4371.